Physician Photo

Jason A. Efstathiou, MD, DPhil

  • Phone: 617-726-5866
Departments
Department of Radiation Oncology

Specialties

  • Cancer Center
  • Radiation Oncology
  • Genitourinary Oncology
Clinical Interests
Prostate cancer
Bladder cancer
Testicular, penile and genito-urinary cancers
Kidney cancer
Ureteral / Urethral cancer
Penile cancer
Proton Beam Therapy
Brachytherapy (radioactive seeds)
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, Harvard Medical School
DPHIL, University of Oxford
Residency, Brigham and Women's Hospital
Board Certifications
Radiation Oncology, American Board of Radiology
Gender
Male
Patient Gateway
Yes, learn more
Patient Age Group
Adult
Accepting New Patients
Yes

Biography

Dr. Efstathiou holds a B.S. from Yale University, M.D. from Harvard Medical School (HMS), Ph.D. from University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program. He serves as Associate Professor of Radiation Oncology at HMS and MGH. His clinical practice focuses on treatment of patients with prostate, bladder, testicular and other urologic cancers, as well as proton beam and brachytherapy. His commitment to service/patient care has been recognized as honoree for the MGH Cancer Center's "The One Hundred" and as nominee for the Brian A. McGovern Award for Clinical Excellence. His research has informed clinical practice guidelines and focuses on the effectiveness of advanced/emerging therapies for prostate cancer including proton beam, as well as the adverse effects of hormonal therapy, improving radiation therapy for testicular cancer, and long-term outcomes of bladder-sparing chemoradiation for bladder cancer. He is the recipient of significant grant funding and serves as Principal Investigator of multiple studies including a multi-center randomized phase III trial of IMRT versus proton beam for localized prostate cancer using patient-reported outcomes. He lectures nationally and internationally and holds leadership positions in Radiation Oncology including within the cooperative groups (NRG), professional societies (ASTRO), and National Cancer Institute (NCI). Other projects of his include the development of web-based patient decision aids/support tools, evaluating the multidisciplinary approach to cancer care, and global oncology outreach efforts with Botswana.

Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by MGH researchers

Clark Center for Radiation Oncology
100 Blossom Street
COX 3
Boston, MA 02114-2606

Phone: 617-726-5866
Fax: 617-726-3603